Scientific presentations

Phelan McDermid Syndrome Foundation - Interview with Neuren Pharmaceuticals about upcoming Phelan-McDermid clinical trial
Publication in Pediatric Neurology: Berry-Kravis E et al., A Double-Blind, Randomized, Placebo-Controlled Clinical Study of Trofinetide in the Treatment of Fragile X Syndrome
Poster at 72nd Annual Meeting of American Academy of Neurology

Trofinetide: a novel approach to Rett syndrome. Neul JL, Percy AK, Benke TA, Berry-Kravis EM, Glaze DG, Jones NE, Youakim JM.

Publication in Neurology®: Double-blind, randomized, placebo-controlled study of trofinetide in pediatric Rett syndrome
Poster at 2016 Rett Syndrome Symposium
Improving outcome measures for Rett Syndrome (RTT) clinical trials: Development of CSS/MBA change indexes to assess treatment outcome
Presentation by Daniel Glaze, MD, at 2016 Rett Syndrome Symposium
Past, Present and Future: A program to develop and establish Trofinetide as a safe and effective treatment for Rett syndrome
Presentation at 6th Annual TBI Conference, Washington DC
A Randomized, Double-Blind, Placebo-Controlled, Dose-Escalation Study of NNZ-2566 in Patients with Traumatic Brain Injury
Poster at American Academy of Neurology 2015 Annual Meeting
NNZ-2566: A Novel, Experimental Treatment for Rett Syndrome
Poster at International Meeting for Autism Research (IMFAR)
Improving outcome measures for Rett Syndrome (RTT) clinical trials: the development of RTT-specific anchors for the Clinical Global Impression Scale
Poster at 2013 FRAXA Investigators Meeting
The Impact of NNZ-2591 on the fmr1 Knockout Mouse Model of Fragile X Syndrome